Korean J Radiol.  2008 Jun;9(3):250-257. 10.3348/kjr.2008.9.3.250.

A Comparison of Low-Dose and Normal-Dose Gadobutrol in MR Renography and Renal Angiography

• Bayrak IK
• Ozmen Z
• Nural MS
• Danaci M
• Diren B

• KMID: 1758459
• DOI: http://doi.org/10.3348/kjr.2008.9.3.250

Abstract

OBJECTIVE
It has been advocated that a reduced injection volume with highly concentrated (1 M) contrast material can produce a sharper bolus peak and an increased intravascular first-pass gadolinium concentration when compared with the use of a lower concentration (0.5 M). A higher concentration would also cause a reduction in dose. The purpose of our study was to test the use of a low dose (0.05 mmol/kg) of gadobutrol in magnetic resonance renography and angiography and compare the findings with a dose of 0.1 mmol/kg. MATERIALS AND METHODS: One-hundred-thirty-four patients referred for magnetic resonance angiography for suspected renovascular disease participated in the study. Contrast enhanced MR renography and angiography were performed after administration of a bolus of 0.1 mmol/kg or 0.05 mmol/kg gadobutrol in randomized patients. The relative signal intensity-time curves of the aorta, peripheral cortex and parenchyma, were obtained. Two radiologists evaluated the angiographic images and evaluated the quality of angiography. RESULTS: The signal intensity with a low dose of gadobutrol was significantly lower in early phases, in the peripheral cortex (for 36, 54, 72 and 90 seconds), the parenchyma (for 36, 54, 72 seconds) and the aorta (for 18, 36, 54, 72 seconds). The decreases in the early phase obtained with a low dose of gadobutrol caused blunter time intensity curves. The difference in the quality scores of the readers for the angiographic images for the use of the two different doses was not statistically significant (p > 0.05). CONCLUSION: A lower dose of gadobutrol can be used for MR renal angiography, but for MR renography the normal dose should be used.

Keyword

Magnetic resonance (MR); Contrast agent angiography; Genitourinary tract; Kidney; Functional imaging; Renography; Angiography

MeSH Terms

Contrast Media/*administration & dosage
Female
Humans
Hypertension, Renovascular/*diagnosis
Magnetic Resonance Angiography/*methods
Magnetic Resonance Imaging/*methods
Male
Middle Aged
Organometallic Compounds/*administration & dosage

Figure

• 

  Fig. 1 Region of interest includes cortex, parenchyma and aorta.

• 

  Fig. 2 MR angiography and MR renographic images of patient after administration of 0.1 mmol/kg gadobutrol.

• 

  Fig. 3 MR angiography and MR renographic images of patient after administration of 0.05 mmol/kg gadobutrol.

• 

  Fig. 4 Relative intensity-time curves of cortex (A), parenchyma (B) and aorta (C). As seen, significant difference was seen between two different dose groups in first 72 seconds.

Reference

1. Rusinek H, Kaur M, Lee VS. Renal magnetic resonance imaging. Curr Opin Nephrol Hypertens. 2004. 13:667–673.

2. Leiner T, de Haan MW, Nelemans PJ, van Engelshoven JM, Vasbinder GB. Contemporary imaging techniques for the diagnosis of renal artery stenosis. Eur Radiol. 2005. 15:2219–2229.

3. Ros PR, Gauger J, Stoupis C, Burton SS, Mao J, Wilcox C, et al. Diagnosis of renal artery stenosis: feasibility of combining MR angiography, MR renography, and gadopentetate-based measurements of glomerular filtration rate. AJR Am J Roentgenol. 199. 165:1447–1451.

4. Grenier N, Trillaud H, Combe C, Degreze P, Jeandot R, Gosse P, et al. Diagnosis of renovascular hypertension: feasibility of captopril-sensitized dynamic MR imaging and comparison with captopril scintigraphy. AJR Am J Roentgenol. 1996. 166:835–843.

5. Lee VS, Rusinek H, Noz ME, Lee P, Raghavan M, Kramer EL. Dynamic three-dimensional MR renography for the measurement of single kidney function: initial experience. Radiology. 2003. 227:289–294.

6. Schoenberg SO, Rieger JR, Michaely HJ, Rupprecht H, Samtleben W, Reiser MF. Functional magnetic resonance imaging in renal artery stenosis. Abdom Imaging. 2006. 31:200–212.

7. Gandy SJ, Sudarshan TA, Sheppard DG, Allan LC, McLeay TB, Houston JG. Dynamic MRI contrast enhancement of renal cortex: a functional assessment of renovascular disease in patients with renal artery stenosis. J Magn Reson Imaging. 2003. 18:461–466.

8. Danielson M, Dammstrom B. The prevalence of secondary and curable hypertension. Acta Med Scand. 1981. 209:451–455.

9. Lewin A, Blaufox MD, Castle H, Entwisle G, Langford H. Apparent prevalence of curable hypertension in the Hypertension Detection and Follow-up Program. Arch Intern Med. 1985. 145:424–427.

10. Tollefson DF, Ernst CB. Natural history of atherosclerotic renal artery stenosis associated with aortic disease. J Vasc Surg. 1991. 14:327–331.

11. Caps MT, Perissinotto C, Zierler RE, Polissar NL, Bergelin RO, Tullis MJ, et al. Prospective study of atherosclerotic disease progression in the renal artery. Circulation. 1998. 98:2866–2872.

12. Staks T, Schuhmann-Giampieri G, Frenzel T, Weinmann HJ, Lange L, Platzek J. Pharmacokinetics, dose proportionality, and tolerability of gadobutrol after single intravenous injection in healthy volunteers. Invest Radiol. 1994. 29:709–715.

13. Tombach B, Heindel W. Value of 1.0-M gadolinium chelates: review of preclinical and clinical data on gadobutrol. Eur Radiol. 2002. 12:1550–1556.

14. Tombach B, Bremer C, Reimer P, Schaefer RM, Ebert W, Geens V, et al. Pharmacokinetics of 1M gadobutrol in patients with chronic renal failure. Invest Radiol. 2000. 35:35–40.

15. Balzer JO, Loewe C, Davis K, Goyen M, Leiner T, Meaney JF, et al. Safety of contrast-enhanced MR angiography employing gadobutrol 1.0 M as contrast material. Eur Radiol. 2003. 13:2067–2074.

16. Goyen M, Lauenstein TC, Herborn CU, Debatin JF, Bosk S, Ruehm SG. 0.5 M Gd chelate (Magnevist) versus 1.0 M Gd chelate (Gadovist): dose-independent effect on image quality of pelvic three-dimensional MR-angiography. J Magn Reson Imaging. 2001. 14:602–607.

17. Herborn CU, Lauenstein TC, Ruehm SG, Bosk S, Debatin JF, Goyen M. Intraindividual comparison of gadopentetate dimeglumine, gadobenate dimeglumine, and gadobutrol for pelvic 3D magnetic resonance angiography. Invest Radiol. 2003. 38:27–33.

18. Tombach B, Benner T, Reimer P, Schuierer G, Fallenberg EM, Geens V, et al. Do highly concentrated gadolinium chelates improve MR brain perfusion imaging? Intraindividually controlled randomized crossover concentration comparison study of 0.5 versus 1.0 mol/L gadobutrol. Radiology. 2003. 226:880–888.

19. Fink C, Puderbach M, Ley S, Risse F, Kuder TA, Bock M, et al. Intraindividual comparison of 1.0 M gadobutrol and 0.5 M gadopentetate dimeglumine for time-resolved contrast-enhanced three-dimensional magnetic resonance angiography of the upper torso. J Magn Reson Imaging. 2005. 22:286–290.

20. Fink C, Puderbach M, Ley S, Plathow C, Bock M, Zuna I, et al. Contrast-enhanced three-dimensional pulmonary perfusion magnetic resonance imaging: intraindividual comparison of 1.0 M gadobutrol and 0.5 M Gd-DTPA at three dose levels. Invest Radiol. 2004. 39:143–148.

21. Prokop M, Schneider G, Vanzulli A, Goyen M, Ruehm SG, Douek P, et al. Contrast-enhanced MR Angiography of the renal arteries: blinded multicenter crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine. Radiology. 2005. 234:399–408.

22. Schoenberg SO, Knopp MV, Londy F, Krishnan S, Zuna I, Lang N, et al. Morphologic and functional magnetic resonance imaging of renal artery stenosis: a multireader tricenter study. J Am Soc Nephrol. 2002. 13:158–169.

23. Bongers V, Bakker J, Beutler JJ, Beek FJ, De Klerk JM. Assessment of renal artery stenosis: comparison of captopril renography and gadolinium-enhanced breath-hold MR angiography. Clin Radiol. 2000. 55:346–353.

24. Choyke PL, Kobayashi H. Functional magnetic resonance imaging of the kidney using macromolecular contrast agents. Abdom Imaging. 2006. 31:224–231.

25. Muhler A. Assessment of myocardial perfusion using contrast-enhanced MR imaging: current status and future developments. MAGMA. 1995. 3:21–33.

26. Heiland S, Benner T, Reith W, Forsting M, Sartor K. Perfusion-weighted MRI using gadobutrol as a contrast agent in a rat stroke model. J Magn Reson Imaging. 1997. 7:1109–1115.

27. Balzer JO, Loewe C, Davis K, Goyen M, Leiner T, Meaney JF, et al. Safety of contrast-enhanced MR angiography employing gadobutrol 1.0 M as contrast material. Eur Radiol. 2003. 13:2067–2074.